STRYKER sees a downgrade to Slightly Negative on account of less fundamental stars
The independent financial analyst theScreener just lowered the general evaluation of STRYKER (US), active in the Medical Equipment industry. As regards its fundamental valuation, the title now shows 1 out of 4 stars while market behaviour can be considered moderately risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Slightly Negative. As of the analysis date February 1, 2022, the closing price was USD 248.60 and its target price was estimated at USD 232.58.Stryker is a medical technology company. The company provides products and services in orthopaedics, medical and surgical, and neurotechnology and spine. The company's Orthopaedics products consist of implants used in hip and knee joint replacements and trauma and extremities surgeries. The company's MedSurg products include surgical equipment and navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices and other medical device products used in a range of medical specialties. The company's Neurotechnology and Spine products include neurosurgical, neurovascular, and spinal implant devices.
Empowering Investors
theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.
- Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization. theScreener state of art: We provide
- theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
- For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.